key: cord-0980656-f77z2hui
authors: Calvo Fernández, Ester; Zhu, Lucie Y.
title: Racing to immunity: Journey to a COVID‐19 vaccine and lessons for the future
date: 2020-12-01
journal: Br J Clin Pharmacol
DOI: 10.1111/bcp.14686
sha: 569886a037368f6eb2ba25d5dc1764a98f213217
doc_id: 980656
cord_uid: f77z2hui

SARS‐CoV‐2 is the novel coronavirus behind the COVID‐19 pandemic. Since its emergence, the global scientific community has mobilized to study this virus, and an overwhelming effort to identify COVID‐19 treatments is currently ongoing for a variety of therapeutics and prophylactics. In order to better understand these efforts, we compiled a list of all COVID‐19 vaccines undergoing pre‐clinical and clinical testing using the WHO and ClinicalTrials.gov database, with details surrounding trial design and location. The most advanced vaccines are discussed in more detail, with a focus on their technology, advantages and disadvantages, as well as any available recent clinical findings. We also cover some of the primary challenges, safety concerns, and public responses to COVID‐19 vaccine trials, and consider what this can mean for the future. By compiling this information, we aim to facilitate a more thorough understanding of the extensive COVID‐19 clinical testing vaccine landscape as it unfolds, and better highlight some of the complexities and challenges being faced by the joint effort of the scientific community in finding a prophylactic against COVID‐19.

Many mild adverse effects are considered acceptable risks to vaccination, but severe reactions that enhance pathogen cytopathogenicity, like antibody-dependent enhancement (ADE) and vaccine-associated enhanced respiratory disease (VAERD), must be avoided. ADE occurs when a vaccine generates antibodies that bind but fail to neutralize its target pathogen. Upon post-vaccination infection, these non-neutralizing antibodies end up facilitating targeted infection of phagocytic immune cells, which respond by producing excessive amounts of pro-inflammatory cytokines, leading to severe inflammation [20] .

VAERD was first clinically observed during a vaccine trial for respiratory syncytial virus (RSV), where vaccinated children developed an accumulation of neutrophils and lymphocytes in the lung upon RSV infection, and where therefore more likely to be hospitalized compared to unvaccinated children [21] . While not mechanistically understood, VAERD correlates with inadequate neutralizing antibody production, inefficient cytotoxic Tcell activation, and inappropriate activation of Th2 and eosinophils in the lung. Since VAERD is primarily seen in infants and young children, it is commonly attributed to low vaccine efficacy and immune system immaturity [22] . Clinical trials must be carefully conducted to avoid these possible effects.

Traditionally, a vaccine may take at least 10 years from conception to implementation. Candidate vaccines are first tested pre-clinically with in vitro and animal models, to determine immunogenicity and toxicity. Then, they must complete three phases of clinical testing before being licensed; Phase I, which confirms vaccine immunogenicity, Phase II, which identifies appropriate dosing and immunization schedules, and Phase III, which tests for efficacy and safety in a larger pool of participants. In order to catch both short-term and long-term effects, each phase can last multiple years, and further pharmacovigilance (Phase IV) is conducted even after a vaccine enters the market. However, when the need for a vaccine is immediate, this process is accelerated by conducting different phases in parallel and shortening the length of each phase [23] . In response to COVID-19, the American Food and Drug Association (FDA) released acceptable trial design guidelines for accelerated vaccine development [24] , making it possible for promising vaccine candidates to apply for Emergency Use Authorization (EUA) [25] . Unlike full licensing, completion of Phase III testing is not required for EUA application, and instead the FDA can actively adjust vaccine implementation strategies in response to supplemental Phase III/IV results. A vaccine is considered successful if it has sufficient interim Phase III safety and efficacy data to show This article is protected by copyright. All rights reserved.

that it reduces the likelihood of developing COVID-19 by ≥50% and "the known and potential benefits of the vaccine outweigh the known and potential risks" [25] (comparatively, the efficacy of the seasonal flu vaccine in the US fluctuated between 19-60% between 2009-2019 [26] ). As it is both dangerous and unethical to inoculate trial participants with SARS-CoV-2, vaccine efficacy is instead determined by comparing the number of COVID-19 cases in placebo-treated participants against that of vaccinated participants.

To consolidate the COVID-19 vaccine landscape, we extracted the list of pre-clinical and clinical vaccine trials from both the WHO database as well as ClinicalTrials.gov (Supplementary Table 1 ) and noted the participant pool's size, age, and geographic region (Supplementary Figure 1) . In total, we identified 221 candidate vaccines being developed or tested for SARS-CoV-2 ( Figure 2 ), and those in the most advanced stages of human trials are discussed in further detail ( Figure 3 ). These vaccines can be broadly classified into four groups based on their components; traditionally inactivated or weakened viruses, viral vectors, nucleic acids, and viral proteins. In addition, we introduce some current efforts to repurpose existing vaccines for COVID-19.

Traditionally, vaccines licensed for human use consisted of viruses that were inactivated or weakened via mutagenesis or neutralizing chemical treatments (e.g.:

formaldehyde, beta-propiolactone) [27] [28] [29] . Since these vaccines physically resemble live virus, they can elicit strong, protective immune responses. However, care must be taken to fully eliminate viral cytopathogenicity before use.

To manufacture inactivated viral vaccines en masse, large amounts of infectious material is needed. Live viral samples are usually collected from multiple patients and replicated in Vero cells, an African green monkey cell line that is susceptible to infection [30] . The strain with the best proliferative ability and lowest mutagenesis rate is then isolated, further proliferated, and inactivated to generate the vaccine. There are currently seven inactivated SARS-CoV-2 vaccines undergoing advanced clinical trials ( Figure 3 ). This article is protected by copyright. All rights reserved.

Beijing-based pharmaceutical company Sinovac Biotech's CoronaVac vaccine combines a SARS-CoV-2 sample sourced from a Chinese hospitalized patient with aluminum adjuvant [31] . In initial animal studies, CoronaVac was found to induce the production of neutralizing antibodies against SARS-CoV-2 in mice and rats [31] . Triple 3µg or 6µg doses of the vaccine also protected against subsequent viral challenge in rhesus macaques, a nonhuman primate capable of developing age-dependent pneumonia in response to SARS-CoV-2 [31, 32] . No immunopathological exacerbations were observed. In Phase I/II trials, results showed that two 3µg doses administered either 14 or 28 days apart resulted in seroconversion in 92.4% and 97.4% of the participants when measured two and three weeks later [33] . In addition, neutralizing antibody titres decreased with participant age , and both doses were well tolerated [33] . A Phase III clinical trial enrolling frontline healthcare professionals launched in Brazil on July 2 nd , 2020 (PROFISCOV, ClinicalTrials.gov NCT04456595) followed by trials in Indonesia (NCT04508075) and Turkey (NCT04582344). In China, CoronaVac is already approved for emergency use by essential workers and high risk individuals [34] , and Phase I/II trials are underway to determine its safety and immunogenicity in both children over 3 and adults over 60 (ClinicalTrials.gov NCT04551547, NCT04383574, NCT04617483).

The Chinese pharmaceutical company Sinopharm is developing an inactivated vaccine with the Wuhan Institute of Biological Products. Currently unnamed, this vaccine uses a SARS-CoV-2 strain isolated from a patient at Wuhan's Jinyintan Hospital, and is enhanced with aluminum adjuvant [35] . It was also the first inactivated vaccine to initiate Phase III testing.

Phase I trials in which 72 participants (18-59) received either triple doses of 2.5µg, 5µg, or 10µg vaccine reported 97% seroconversion two weeks after the final injection [35] .

Interim analysis from a Phase II trial conducted in parallel showed that two doses of 5µg administered across 14 or 21 days achieved similar immunogenicity outcomes (41 out of 42 vaccinated participants, 97.6%) [35] . Both trials reported a low rate of mild adverse reactions, with the most common being pain at the site of injection and fever [35] . In June, Phase III trials began with 15,000 participants in the UAE (Chinese Clinical Trial Registry, This article is protected by copyright. All rights reserved.

ChiCTR2000034780), and has since expanded to Jordan, Bahrain (ClinicalTrials.gov, NCT04510207), and Morocco (ChiCTR2000039000) for an estimated total of 45,600 participants. On September 14th 2020, the United Arab Emirates approved the use of this vaccine as an emergency prophylaxis for healthcare workers [36] .

Sinopharm is also working with the Beijing Institute of Biological Products to create a second inactivated vaccine with aluminum adjuvant, BBiBP-CorV [37] . In pre-clinical trials, two 2 µg doses induced sufficient levels of neutralizing antibody in six mammalian species, including rhesus macaques, and protected against subsequent SARS-CoV-2 challenge [37] . 192 participants in Phase I trials received two doses of 2 µg, 4 µg, or 8µg vaccine, which were well-tolerated and triggered only dosage-dependent mild adverse reactions [38] . While all participants had neutralizing antibodies by 28 days, larger doses resulted in earlier seroconversion, and the vaccine's immunogenicity did not drop with participant age [38] . Subsequent Phase II trials tested either a single 8 µg dose or two 4 µg doses administered either 14 days or 28 days apart. Those who received two doses 28 days apart had the highest antibody titres after three weeks compared to the other treatment groups [38] . Phase III trials are underway in the UAE, Jordan, Egypt, and Bahrain alongside the unnamed Wuhan vaccine mentioned above (ClincalTrials.gov NCT04510207), and a separate Phase III trial for 3,000 participants began September 23 rd in Argentina (NCT04560881).

While live attenuated vaccines are made with intact viruses, viral vector vaccines consists of an replication-deficient or attenuated replication-competent human or chimpanzee adenovirus containing the DNA of the target pathogen's surface protein [27] . In the case of COVID-19, the Spike protein gene is the only component of SARS-CoV-2 incorporated into these vaccines. While only a few viral-vectored vaccines have been approved for viral infections, this platform has been extensively investigated for cancer treatment. Unlike inactivated vaccines, viral vector vaccines have lower cytotoxicity risk (as even nonattenuated adenoviruses only cause mild cold or flu) but are still recognized as viruses by TLRs [39] . However, certain populations, especially in developing countries, may already be immune to these viruses. For example, natural seroprevalence for the commonly used human adenovirus 5 (Ad5) and chimpanzee adenovirus (ChAd), is between 60-90% [40] , and 1-19% This article is protected by copyright. All rights reserved. [41, 42] respectively, with consistently higher rates in Asian and African populations. For these reasons, the efficacy of viral vector vaccines may vary between different ethnic groups.

Developed by Oxford University and AstraZeneca, ChAdOx1 nCoV-19 is made by fusing the SARS-CoV-2 Spike gene to the replication defective chimpanzee adenovirus ChAdOx1 [43] . This design is based on recent Phase I results with ChAdOx1-based vaccines for tuberculosis (TB) and MERS [44, 45] . A single dose generated neutralizing antibodies in mice and rhesus macaques that reduced disease severity and viral load in the lower respiratory tract after subsequent SARS-CoV-2 challenge, but did not prevent infection [46] .

Phase I/II trials were conducted with two doses of 5×10 10 viral particles across 28 days. 91% of participants seroconverted after the first dose, and all participants had neutralizing antibodies after the second [47] . The vaccine was well-tolerated [47] . Following these findings, Phase III trials were approved in the U.S. in August (ClinicalTrials.gov NCT04516746) for 30,000 participants. Phase II/III trials are also being held in the U.K.

(NCT04400838), South America (NCT04516746, NCT04536051), Japan (NCT04568031), and South Africa (NCT04444674), where the vaccine's efficacy will be tested in HIV positive participants.

On September 6 th , all trials were paused after a participant allegedly developed transverse myelitis [48, 49] , a rare but severe neurological condition in which inflammation along the spinal cord results in pain, muscle weakness, and paralysis. Transverse myelitis has been linked to vaccines for hepatitis B, measles, and diphtheria in rare instances [50] , and one case was reported in 2009 in response to the H1N1 vaccine [51] . While news of the initial hold was seen as evidence of scientifically rigorous testing [48] , AstraZeneca's decision to restart trials in the UK on September 14 th without disclosing results from the safety investigation triggered calls for transparency and fueled growing suspicions over vaccine safety in the US and UK [52, 53] . After reviewing all safety data, the FDA re-authorized ChAdOx1 nCov-19 trials in the US on October 23 rd , marking the complete resumption of all AstraZeneca trials globally [54] .

This article is protected by copyright. All rights reserved.

On November 23 rd , AstraZeneca announced Phase III interim analysis results, in which the vaccine was reported to be 90% effective when administered in two doses of 2.5×10 10 and 5×10 10 viral particles at least one month apart, and 62% efficacy when administered as two doses of 5×10 10 viral particles at least one month apart [55] . Of the 131 COVID-19 cases identified, vaccinated participants with COVID-19 did not experience severe symptoms or require hospitalization. The report also claimed that no vaccine-triggered severe adverse events have been reported. As with most vaccines, ChAdOx1 nCoV-19 can be stored and transported at regular refrigeration temperatures (2 ~ 8°C) and last at least six months [55] .

The Chinese vaccine company CanSino Biologics is developing a viral vector vaccine using a replication-defective form of the human adenovirus Ad5 and the SARS-CoV-2 Spike gene. During pre-clinical trials, Ad5-nCov sufficiently protected ferrets and mice from SARS-CoV-2 challenge [56] . In subsequent Phase I trials, the vaccine was tested at three different doses (5×10 10 , 1×10 11 , and 1·5×10 11 viral particles), and dose-dependent titres of neutralizing antibodies were detected by day 14 [57] . Since those who received the highest dose experienced higher reactogenicity including reports of severe fever, fatigue, dyspnea, muscle pain, and joint pain [57] , Phase II trials focused on the two lower doses, and confirmed that both could induce seroconversion and were well-tolerated [58] . This vaccine is currently undergoing Phase II testing in children ≥6 and adults ≥56 in China (NCT04566770), and Phase III trials in Russia (NCT04540419) and Pakistan (NCT04526990).

Johnson & Johnson is developing the viral vector vaccine Ad26.COV2.S using Ad26, a human adenovirus that has lower natural seroprevalence rates than Ad5 (43-68% in African populations) [41, 59] . The vaccine effectively protected rhesus macaques and hamsters from SARS-CoV-2 challenge in pre-clinical trials [60, 61] . Phase I/II trials identified single doses of 5×10 10 or 1×10 11 viral particles sufficient to trigger neutralizing antibodies in 92% of participants a month after vaccination [62] . Two Phase III trials are being conducted; the first, which began on August 10 th , is testing single doses of 1×10 11 viral particles on 60,000 participants within the US, South America, Southeast Asia, South Africa and parts of This article is protected by copyright. All rights reserved.

Europe (ENSEMBLE, ClinicalTrials.gov NCT04505722), while a second is testing a twodose regimen in the UK, France, the US, and South Africa (ENSEMBLE2, NCT04614948).

On October 12 th , Johnson and Johnson placed a temporary pause on all clinical trials in response to an unexplained illness in a study participant. This pause was lifted on October 23 rd with FDA approval, after an independent investigation found no connection between it and the vaccine. [63, 64] . At time of writing, no details have been released regarding the nature of the illness.

Research Institute of Epidemiology and Microbiology. Unlike other viral vector vaccines, Gam-COVID-Vac is a heterologous formulation consisting of two human adenovirus vectors, Ad26 and Ad5, both carrying the SARS-CoV-2 Spike gene. Phase I/II trials from June found that a single dose of 1×10 11 viral particles triggered seroconversion in all 76 participants by 42 days post-injection [65] . Despite doubt from the scientific community, the vaccine gained regulatory approval in Russia on August 11 th [66] . In September, Phase III trials began in Russia with 40,000 participants (RESIST, ClinicalTrials.gov NCT04530396) in which the vaccine was administered in two doses 21 days apart, and on October 27 th , Gam-COVID-Vac became the first COVID-19 vaccine submitted to the WHO for approval [67] . In an interim report published on November 22 nd , Gamaleya claimed its vaccine was 92% effective after the first dose based on 20 COVID-19 cases across 16,000 participants [68] . By November 24 th , updated reports describe the vaccine as being 91.4% and 95% effective at 7 and 21 days respectively, and after both doses have been administered, based on a total of 39 confirmed COVID-19 cases [69] . Both reports note the absence of unexpected adverse effects, and Gamaleya intends to release a third interim analysis once 78 COVID-19 cases have been recorded [68, 69] . These results have yet to be formally published.

Gene-based approaches to vaccine development represent a new way of approaching immunization [70] . By directly introducing fragments of viral genomic material in the form of DNA or RNA into host cells, these vaccines provide cells with the information necessary to express and present viral antigens to the immune system. Since only the viral genetic This article is protected by copyright. All rights reserved.

sequence is required, nucleic acid vaccines are cheap, safe, and relatively easy to design and manufacture. However, this strategy comes with its own set of unique challenges. Although the structure of DNA contributes to its stability, RNA is chemically reactive and therefore prone to self-cleavage and degradation by ribonucleases, and while these vaccines are stabilized inside lipid nanoparticles [70] , RNA vaccines remain much more vulnerable compared to vaccines containing DNA, protein or whole viral particles [71] . For this reason, the temperature and storage conditions of RNA vaccines needs to be determined empirically, and more regulation will likely be necessary for distribution and administration. DNA vaccines are also uniquely complicated; unlike other vaccines, DNA vaccines must enter the cell nucleus to drive antigen expression. Since the nuclear membrane is less porous than the plasma membrane, these vaccines must be administered with a gene gun [27] , which also must be tested to ensure efficacy and safety.

While recombinant plasmid DNA has been explored as a vaccine platform for decades, the possibility of using RNA for human vaccine development is rather new [71] [72] [73] .

To date, only a few RNA-based treatments are in use, including the small interfering RNA (siRNA) therapies Givlaari (givosiran) for acute hepatic porphyria [74] and Onpattro (patisiran) for polyneuropathy of hereditary TTR-mediated amyloidosis [75] . While nucleic acid vaccines hold promise, the relative lack of existing DNA/RNA prophylactics mean that relatively less is known about its safety profile, reliability, and feasibility compared to other vaccine platforms.

BioNTech, a German pharmaceutical company, is currently pursuing the development of its nucleoside-modified mRNA vaccine BNT162b2 in partnership with Pfizer. BNT162b2 consists of the full-length SARS-CoV-2 Spike protein mRNA encased in a lipid nanoparticle. In Phase I, this vaccine triggered neutralizing antibodies titres 1.8 to 2.8 times higher than titres seen in recovered COVID-19 patients [76] . In addition, both Phase I and II trials revealed only mild to moderate side effects, including fever, chills, and fatigue, and identified a two-dose regimen across 21 days as the most appropriate for subsequent trials [77] . Phase III trials began in Germany in May (ClinicalTrials.gov NCT04537949) followed by additional Phase II/III trials in the US, parts of South America, and South Africa (NCT04365728). In August, Phase I trials were approved in China (NCT04523571). On This article is protected by copyright. All rights reserved.

October 12 th , Pfizer announced that Phase III trials in the US were being expanded to include children as young as 12 years old, making it the first US/European-based COVID-19 vaccine tested in individuals under 18 years of age [78] . Although COVID-19 hospitalization and mortality rates are lowest in this age group, 10.7% of US COVID-19 cases occur in children, making them significant sources of viral spread [79] .

On November 9 th , Pfizer announced initial Phase III interim reports describing its vaccine as having up to 90% efficacy against SARS-CoV-2 [80] . By November 18 th , the company officially concluded its Phase III trial [81] and reported its vaccine as being 95% effective. A total of 170 COVID-19 cases were identified in 43,661 participants tested seven days after completing the treatment or placebo. Of these, 162 cases belonged to the placebo group, and 8 from vaccinated participants. Furthermore, of the 10 severe COVID-19 cases observed, 9 occurred in the placebo group [81] .The report also stated a lack of severe safety concerns across its ethnically diverse participant pool, and consistent vaccine efficacy across gender and race demographics. The vaccine was similarly effective in participants ranging from 18 to 85 years of age [81] . As BNT162b2 was empirically determined to be most stable at -70°C [81] , the company is currently working to establish reliable cold-chain distribution and storage methods. This report does not discuss the vaccine's efficacy in individuals with comorbidities. As of time of writing, Pfizer has applied for EUA with the FDA and is preparing to manufacture 50 million doses of this vaccine by the end of 2020 [81] .

American biotech company Moderna is home to mRNA-1273, which consists of the SARS-CoV-2 Spike protein's mRNA encapsulated in a lipid nanoparticle [82, 83] . Designed only 45 days after the SARS-CoV-2 genome was sequenced, mRNA-1273 elicited neutralizing antibodies in a dose-dependent fashion within two weeks of vaccination in Phase I trials [83] . Three immunization regiments were tested: two injected doses of 25µg or 100µg, and a single 250µg dose. While no serious vaccine-related adverse events were reported, ≥50% of participants experienced mild events including fatigue, chills, headache, myalgia, and pain at the injection site, and the single concentrated dose correlated with more moderate adverse events. Subsequent Phase II testing determined that two doses of 100µg was most appropriate (ClinicalTrials.gov NCT04405076) and Phase III trials, which began recruiting This article is protected by copyright. All rights reserved.

on July 14 th across the United States, prioritized high-risk individuals including healthcare workers and those with underlying medical conditions (COVE, NCT04470427).

On November 16 th , and with 30,000 participants enrolled, Moderna's mRNA vaccine became the second of its kind to release interim Phase III analysis [84] . cases were identified in participants tested two weeks after the second injection. Of these, 90 came from the placebo group, and 5 from the vaccinated group. Importantly, 11 cases were described as being "severe", all of which came from the placebo group. Based on these results, Moderna concluded its vaccine to be 94.5% effective. Up to now, there have been no reports of severe adverse effects, and no safety concerns have been raised [84] . This report also emphasized the ethnic and medical diversity of the participants tested, of which 37% belonged to communities of colour, and 42% were high-risk due to existing comorbidities [84] . The vaccine appears to be stable for up to a month in a standard refrigerator (2~8°C), and can be stored for up to 6 months at standard freezer temperatures (-25 ~ -15°C) [85] , making it less challenging to administer compared to Pfizer's mRNA vaccine. The trial intends to be maintained until at least 151 COVID-19 cases are identified, and participants will be followed up with continued testing until two months post-treatment.

Of the four DNA-based COVID-19 vaccines in clinical trials, none have advanced to Phase III trials ( Figure 3) and little is known about their efficacy. For example, INO-4800, which contains the Spike protein gene, is currently being developed by U.S. biotechnology company Inovio Pharmaceuticals. Preclinical results in mice and guinea pigs examined the vaccine's immunogenicity [86] . As a proof of concept, a separate group independently created a DNA vaccine with the same genetic material, and reported that it could elicit neutralizing antibody production in rhesus macaque which protected against (but did not prevent) subsequent SARS-CoV-2 challenge [87] . Interim Phase I results reported by the company stated neutralizing antibodies were induced in 94% of participants (40 total), with no significant safety concerns [88] . On November 16 th , Phase II/III trials were announced to further test the safety and efficacy of both INO-4800 as well as the gene gun being used to administer this vaccine directly through the skin, but as of writing, recruitment has not yet begun [89]. This article is protected by copyright. All rights reserved.

In direct contrast to other vaccine approaches, protein-based vaccines contain only viral proteins without any genomic material, and therefore run no risk of becoming infectious [90] . These vaccines are made either with protein subunits (fragments of viral surface protein) or virus-like particles (nanostructures that resemble the outer viral envelope).

Protein subunit vaccines contain recombinant viral surface proteins packaged in a way that mimics the viral target. For these vaccines, the protein is made and purified from non-mammalian systems using laboratory methods and assembled in vitro. While this design permits more control over the shape and density of the viral proteins presented to the immune system, these vaccines are also more sensitive to improper epitope conformations [91, 92] . While also assembled in vitro, virus-like particles (VLPs) differ in that it consists of multiple different viral structural proteins. In the case of SARS-CoV-2, VLPs contain the Spike protein co-assembled with the M, E, and sometimes N coronavirus envelope proteins, all purified from eukaryotic expression systems [91, 92] . Several approved commercial vaccines, including those for human papillomavirus and hepatitis B, are based on VLPs, so its biology and safety profiles are well-established, and they can be safely and easily massproduced [93] . To date, only two COVID-19 VLP vaccines are in clinical testing: RBD-HBsAg VLP and an Unnamed VLP vaccine, in Phase I/II and Phase I respectively.

NVX-CoV2373 is a protein subunit vaccine developed by Novavax, consisting of the SARS-CoV-2 Spike protein, and is the most advanced COVID-19 vaccine with this platform. The vaccine is formulated with Novavax's patented Matrix-M™ adjuvant, a saponin-based adjuvant that stimulates entry of antigen-presenting cells into the injection site to enhance immune system activation [94, 95] to produce stronger, long-lasting immune responses. Novavax recently announced results from Phase I/II trials showing that the This article is protected by copyright. All rights reserved.

vaccine was well-tolerated and that two doses of 5µg was sufficient to induce neutralizing antibody titres exceeding those found in convalescent serum from symptomatic Covid-19 patients [94, 96] . In October, Novavax began Phase III clinical trials in the United Kingdom with healthy adult participants (ClinicalTrials.gov NCT04583995), and in November, additional Phase III trials were initiated in the US and Mexico to recruit high-risk participants (NCT04611802).

Alongside global efforts to develop and test COVID-19 vaccines, various groups have been exploring the possibility of repurposing existing vaccines for COVID-19. These efforts are built upon prior knowledge of vaccine non-specific effects (NSEs). NSE is a phenomenon by which the administration of one vaccine improves or impairs one's response to unrelated pathogens, likely because the vaccine modified components of the immune system [97] . Vaccine NSEs were first recognized in the 1970s, when the introduction of a live attenuated measles vaccine to low-income countries led to reductions in mortality in vaccinated children that could not be explained by protection against measles infection alone [98] . Since then, numerous observational studies in children from both low-income and high-income settings show that immunization with live attenuated vaccines, such as those against measles, smallpox, TB, and polio can have broad beneficial NSEs while immunization using non-live vaccines, including inactivated vaccines for polio, diphtheria, tetanus, pertussis (DTP), hepatitis B, and seasonal influenza, do not [98] . In some cases, childhood immunization with non-live vaccines have been shown to actually increase susceptibility to unrelated infections in girls, however the same effect have not been found in boys [98] . In cases where live and non-live vaccines were administered in combination, the vaccine administered last dictated NSEs, and individuals with prior immunity to the targeted pathogen can still experience NSEs upon re-vaccination [98] . Based on these findings, clinical trials are underway to determine if existing live-attenuated vaccines can protect against SARS-CoV-2. Since these vaccines are already FDA-approved, have known safety profiles, and are generally accessible as they are routinely administered around the world, they can be easily repurposed as temporary prophylactics if a COVID-19 vaccine is unavailable. This article is protected by copyright. All rights reserved.

The measles, mumps, and rubella vaccine, MMR, is a cocktail comprised of liveattenuated strains of the three highly contagious RNA viruses that, while not incurable, can trigger a host of serious health complications [99] . Developed in the 1970s, the MMR is the main vaccine provided worldwide to protect against these viruses. In the US, the CDC recommends the MMR vaccine to be administered to children before age 6, as well as to high-risk adults (i.e. health care workers). Studies of children in the US [100] , Italy [101] , Denmark [102, 103] , and the Netherlands [104] show that children who were most recently vaccinated with MMR had reduced rates of hospital admissions for other respiratory illnesses, including RSV, compared to children who were most recently vaccinated with nonlive vaccines.

The SARS-CoV-2 Spike protein is 20% identical to that of the rubella virus, and COVID-19 patients with higher circulating rubella antibodies reportedly experience lower SARS-CoV-2 viral burden [105] . Additionally, two unreviewed epidemiological studies suggest a negative correlation between MMR immunization rates and COVID-19 rates and symptom severity, both globally and across 37 North American and European countries [106, 107] . The same trends were not found between COVID-19 and DTP immunization rates [107] . The Washington University School of Medicine is leading the effort to determine if MMR protects against COVID-19 infection through a Phase III trial (CROWN CORONA, ClinicalTrial.gov NCT04333732) in healthcare workers.

The Bacille Calmette-Guerin vaccine (BCG) is a live-attenuated vaccine containing the bacteria Mycobacterium bovis, which was isolated in 1900 from the milk of a cow with bovine TB and attenuated by repeated passaging on potatoes [108] . Today, it remains the main prophylactic treatment for human TB. The BCG vaccine is usually administered intradermally on the upper arm, where it leaves behind a small scar. Unlike MMR, the efficacy of BCG against TB is disputable, and has been reported to fall anywhere between 0% to over 80% [109] due to the heterogenous nature of TB as well as variations between different attenuated M. bovis cultures around the world [110] . For this reason, BCG vaccine administration policies differ significantly between regions; in most of Asia, Africa, and This article is protected by copyright. All rights reserved.

South America, BCG is universally administered to newborns, while in Australia, as well as parts of Europe and North America, it is only recommended for at-risk communities [110] .

The broad beneficial NSE of BCGs have been well documented worldwide, as immunization correlates with lower neonatal mortality rates than can be expected from protection against TB alone [111] [112] [113] . Furthermore, BCG appears to confer non-specific, potentially long-lasting protection against lower respiratory tract infections [114, 115] .

However, given that BCG is usually not administered to adults, it is unclear if these benefits exist in later life. Epidemiological analysis of socially similar European countries and communities in Japan identified a negative correlation between BCG vaccination levels and COVID-19 mortality [116, 117] . Globally, BCG-vaccinated countries appears to have lower COVID-19 prevalence rates compared to countries without a BCG vaccination program [118, 119] . To determine if BCG protects against COVID-19 infection in adults, Phase III studies with healthcare workers are currently underway in multiple countries, including the Netherlands (BRACE, ClinicalTrials.gov NCT04327206) and Australia (BCG-CORONA, NCT04328441).

The Oral Polio Vaccine is made by combining attenuated versions of the three poliovirus serotypes behind poliomyelitis [120] . Vaccination for the poliovirus, which, like SARS-CoV-2, is a +ssRNA virus, can occur at any age, and communities in polio-prone regions often receive regular booster shots [121] . Unfortunately, while OPV is effective against poliomyelitis, it has been known to "de-attenuate" and create a vaccine-generated poliovirus that, over time, can trigger a polio outbreak similar to that created by regular poliovirus. Because of this, proper eradication of the poliovirus requires a two-pronged approach; an initial treatment with the attenuated OPV, followed by secondary treatment using an inactivated, injectable polio vaccine (IPV) to eliminate the potential development of vaccine-generated poliovirus. As OPV is cheaper and easier to produce, transport, and administer compared to IPV, it is much more accessible, which is one of the reasons why polio continues to persist in certain developing countries [121] . Similar to the other liveattenuated vaccines introduced above, the NSEs of OPV are largely beneficial, ranging from general reduction in infant mortality [122] [123] [124] , to protection against childhood diarrhea [125] and ear infections [126] . Phase III trials testing the effect of OPV on COVID-19 rates This article is protected by copyright. All rights reserved. are currently underway in the US (OPV-NA831, ClinicalTrials.gov NCT04540185) and

Guinea-Bissau (NCT04445428).

In the past year, our understanding of the SARS-CoV-2 virus has expanded at a truly unprecedented rate. While the vaccines summarized here represent only a small fraction of the scientific accomplishments achieved by research groups working around the worldand around the clockthe strain this pandemic has brought to our global community sheds light on certain cracks in our system that must be addressed. [128] and the simple fact that three of the seven zoonotic coronaviruses to date are capable of significantly reducing our quality of life, it would be imprudent not to prepare for future coronavirus epidemics. Further research into coronaviruses and efforts to develop therapies must persist even after COVID-19 elimination so that communities may be more prepared to respond. Efforts to track the biology and evolution of other coronavirus strains should be made so that we may predictand minimizefuture animal-to-human transmission. Indeed, predictions of a second zoonotic SARS-CoV virus emerged as early as 2007 [129] , but was largely ignored. With the right knowledge, preparation, and support from scientifically driven policies, future coronavirus-based epidemic scan and should be mitigated.

This article is protected by copyright. All rights reserved.

Given the speed of SARS-CoV-2 transmission around the globe despite lockdown and travel restrictions, it is clear that no country will be safe from infection without concerted efforts worldwide. The success or failure of virus eradication policies depend largely on vaccine accessibility and distribution. For many low-income countries, the lack of infrastructure and funds necessary to acquire, transport, and administer vaccines can prevent disease eradication. For example, while the WHO-funded campaign to eradicate polio, which was launched in 1985, helped eliminate the disease within the Americas and Europe by 1994 and 2002 respectively, countries including Afghanistan, Pakistan, Nigeria, and the Philippines continue to suffer outbreaks today [130] . In the case of COVID-19, this disparity will be even more serious, as developed countries have already established heavy monopolies on existing SARS-CoV-2 vaccine candidates. The necessity of a coordinated global effort to control viral spread cannot be over-stated, therefore, conversations must be held about SARS-CoV-2 in developing regions, and infrastructure to fund and monitor COVID-19 vaccination will be needed in these communities to facilitate timely global recovery.

This pandemic has also amplified existing challenges involving other viral pathogens. Thanks to the combination of viral persistence in developing countries and a souring attitude towards vaccination in certain developed countries, measleswhich was eliminated from the US in 2000has since re-emerged. Last year, 1276 US cases were reported, and cases are projected to rise in the coming years due to COVID-19 disrupting regular childhood vaccination schedules around the world [131, 132] A similar narrative is predicted for polio, which, prior to the pandemic, was on track for eradication by 2021 [133] .

While not all viruses can be feasibly eradicated due to the presence of non-human reservoirs, long latency periods, or the lack of a vaccine conferring life-long immunity [134] , this is not the case for measles, polio, and a number of other viral diseases. Therefore, to minimize the risk of what are entirely avoidable epidemics, we must take disease eradication seriously where it is applicable, and to do so, effort should be made to address vaccination policies both internationally and here at home. This article is protected by copyright. All rights reserved.

Alongside the pandemic, communities around the world are being overwhelmed by misinformation regarding COVID-19, ranging from trivialization of health risks to downright fraudulent claims of cures and prophylactics [135, 136] . While we have been focusing our efforts on treating the pandemic, this "infodemic" has gone unchecked. Science communication and transparency is crucial to maintaining public trust, especially now, when each new COVID-19 report or finding is heavily scrutinized by the public eye. Currently, the relative obscurity and unusual speed by which drug companies and their academic partners complete trials, as well as concerns over possible political pressure on scientific judgement has both degraded the public's trust in treatments and vaccines and fueled further misunderstanding. This can lead to non-compliance when a vaccine is eventually released, which can delay or prevent COVID-19 elimination.

Undoubtedly, there is a need for clearer communication during clinical trials. When AstraZeneca's viral vector vaccine ChAdOx1 nCov-19 was temporarily halted, this was reported to be due to neurological symptoms in a participant [48, 49] . However, when the pause was lifted in the US, the only announcement made was that the FDA had reviewed the safety data and found it satisfactory [54] . Similarly, Johnson & Johnson's Phase III trial for Ad26.COV2.S was paused for about a week in October with no public report explaining either the reason for the hold or why it was lifted. The absence of official reports can fuel misinformation and mistrust, and while companies need to maintain the confidentiality of trial participants, they must also learn to be more proactive, transparent, and consistent with the public by announcing and explaining major decisions.

One way to prevent misinformation and foster trust is to make details regarding treatment design and clinical trials available to the broader community. So far, Moderna, Pfizer, AstraZeneca, and Johnson & Johnson have all published their Phase III trial protocols, and the FDA has announced its intention to do the same with its scientific review process for COVID-19 EUAs [137] . These documents include details on data collection, participant pool size, known side effects, and how vaccine efficacy was determined. EU regulators are also making an effort to improve transparency around COVID-19 treatments. In particular, the European Medicines Agency (EMA) is publishing all clinical data in support of applications This article is protected by copyright. All rights reserved.

for COVID-19 treatments, along with the full risk management plan generated by the EMA's scientific committees' assessment which powers subsequent commission decision of treatment licensing [138] . Policies such as this foster public trust and promote science literacy over time. We therefore encourage other pharmaceutical companies and research groups to follow suit, and call for continued data transparency in the post-COVID-19 world.

Interim Phase III results have so far reflected a triumph for mRNA vaccines. To date, the Pfizer BNT162b2 and the Moderna mRNA-1273 vaccines are reported to be 95% and 94% effective, respectively, which is significantly higher than the minimal 50% efficacy required by the FDA. If commercialized, these would be the first approved vaccines using RNA. There are clear benefits to nucleic acid vaccines beyond their immunogenicity; unlike all other vaccine platforms, the nucleic acid vaccine production does not rely on live vaccine samples or other biological systems. Genomic material can be quickly and cheaply reproduced in a test tube, and only knowledge about its sequence is necessary for vaccine design. In theory, this minimalistic approach should also allow the same development pipeline to be applied to a large variety of pathogen targets, making this platform suitable for future vaccine development.

While the relative instability and inefficient delivery of nucleic material had previously limited the development of RNA vaccines, recent technological advances in lipid nanoparticle formulation have largely removed the latter barrier [139] . Improvements to nanoparticle design and cold-chain distribution infrastructure are currently being made to address stability concerns, but unless significant progress is made, this vulnerability will likely limit the platform's ability to be used in most developing countries. Hopefully, future technological developments and efforts to concentrate RNA vaccine immunogenicity into a single dose [140] will negate some of these administrative challenges in the coming years.

DNA vaccines are similarly inhibited by challenges in nuclear delivery, and efforts to improve gene gun technologies as part of COVID-19 DNA vaccine development are expected to significantly impact the future prospects of this platform.

Since RNA vaccines have not been commercialized before, little is known about their safety profile and long-term efficacy. So far, interim Phase III safety data have been This article is protected by copyright. All rights reserved. largely positive, but these trials are unlikely to identify rare adverse effects due to limits in participant size and can only provide information on short-term effects observed in the last few months. Since the half-life of RNA material in the body is only a matter of hours, and these vaccines do not contain any other viral material, these treatments are unlikely to trigger unexpected long-term adverse effects. However, little is known about the duration of its conferred immunity in the absence of long-term data. As it becomes more and more likely that an RNA vaccine for COVID-19 will be approved for emergency use, cautious vigilance must be maintained to determine the long-term efficacy and safety of these vaccines over the next months and years in order to determine the suitability of this platform for future vaccine development.

When the FDA announced guidelines for accelerated vaccine development, a number of decisions, including study demographic groups, trial end points, and even the definition of mild versus severe COVID-19 cases were left to the discretion of pharmaceutical companies. This has resulted in small variations in trial design between companies, including the ages and health status of participants, and when to test for COVID-19 after treatment. While these variations do not negate the results from each individual study, they prevent different vaccines from being compared against each other, which is required to determine if certain vaccines are more suitable for certain populations. Normally, additional trials comparing different therapies using the same protocol are conducted, but during a pandemic, we lack the benefit of time.

One solution to this problem is to organize a single massive Phase III trial to simultaneously test various vaccines against COVID-19 and each other, such as the one proposed by the WHO for the EU [141]. While this "Solidarity Trial" is theoretically beneficial and require fewer enrolled participants overall (as all vaccines share the same placebo group), the level of coordination required by all participating parties has led to undesirable delays. In order to make the most out of the limited efficacy and safety data that can be obtained during accelerated vaccine development, without obstructing testing, we propose that certain terms, expected outcomes, and important participant groups should be defined in advance by regulators. Since different therapies necessarily variate in dosing strategies and target populations, pharmaceutical companies should be allowed to opt out of

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

A distinct name is needed for the new coronavirus

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

COVID-19 Reported Deaths: Using Shewhart Control Charts to Understand Variation. Boston: Institute for Healthcare Improvement

Viruses with Single-Stranded, Positive-Sense RNA Genomes

Human coronaviruses: A brief review

A Review of Coronavirus Disease-2019 (COVID-19)

Coronaviruses post-SARS: Update on replication and pathogenesis

The COVID-19 vaccine development landscape

Biological feasibility of developing prophylactic vaccines for viral pathogens: Incubation period as a critical parameter

Certainty of success: three critical parameters in coronavirus vaccine This article is protected by copyright. All rights reserved. development. npj Vaccines

Mechanisms of viral mutation

Why are vaccines against many human viral diseases still unavailable; an historic perspective

COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Immunogenomics and systems biology of vaccines

How the innate immune system senses trouble and causes trouble

Vaccine adjuvants: Putting innate immunity to work

Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs

The potential danger of suboptimal antibody responses in COVID-19

Respiratory virus immunization: A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent paratnfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

Update #37: What we know about COVID-19 vaccine development. WHO.int

Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry

Use Authorization for Vaccines to Prevent COVID-19: Guidance for Industry

Seasonal Flu Vaccine Effectiveness Studies

Fundamentals of vaccine immunology

The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. npj Vaccines

Treatment of influenza virus with Betapropiolactone alters viral membrane fusion

A universal mammalian vaccine cell line substrate

Rapid development of an inactivated vaccine for SARS-CoV-2. bioRxiv

Age-related rhesus macaque models of COVID-19

Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial. medRxiv

Sinovac coronavirus vaccine offered by Chinese city for emergency use costs This article is protected by copyright. All rights reserved

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes

UAE announces emergency approval for use of COVID-19 vaccine | Reuters. Reuters

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy

Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China

Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults

Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime -MVA85A boost in healthy UK adults

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a doseescalation, open-label, non-randomised, uncontrolled, phase 1 trial

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, singleblind, randomised controlled trial

A leading coronavirus vaccine trial is on hold: scientists react

Internal AstraZeneca safety report sheds light on neurological condition suffered by vaccine trial participant -CNN

Transverse myelitis and vaccines: A multi-analysis

Longitudinally extensive transverse myelitis following vaccination with nasal attenuated novel influenza A(H1N1) vaccine

Scientists relieved as coronavirus vaccine trial restarts -but question lack of transparency

COVID-19 vaccine AZD1222 clinical trials resumed in the UK. This article is protected by copyright. All rights reserved

FDA authorises restart of the COVID-19 AZD1222 vaccine US Phase III trial

AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

A single dose of an adenovirus-vectored vaccine provides complete protection of the upper and lower respiratory tracts against SARS-CoV-2 challenge

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, openlabel, non-randomised, first-in-human trial

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, doubleblind, randomized, placebo-controlled trial. medRxiv

Temporarily Pauses All Dosing in Our Janssen COVID-19 Vaccine Candidate Clinical Trials

Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

REGULATORY APPROVAL IN RUSSIA OF A COVID-19 VACCINE DEVELOPED BY GAMALEYA INSTITUTE

Russian Direct Investment Fund. Russian application of Sputnik V vaccine for WHO vaccine prequalification among the first applications submitted

The first interim data analysis of the Sputnik V vaccine against COVID-19 phase III clinical trials in the Russian Federation demonstrated 92% efficacy

Second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose | Official website vaccine against COVID-19 Sputnik V

SARS-CoV-2 Vaccines: Status Report. Immunity. This article is protected by copyright. All rights reserved

mRNA vaccines-a new era in vaccinology

One Group's Historical Reflections on DNA Vaccine Development

The promise of mRNA vaccines: a biotech and industrial perspective. npj Vaccines

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. medRxiv

Current clinical trials protocols and the global effort for immunization against sars-cov-2. Vaccines

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

Children and COVID-19 : State Data Report

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19

Achieved Success in First Interim Analysis from Phase 3 Study

PFIZER AND BIONTECH CONCLUDE PHASE 3 STUDY OF COVID-19 VACCINE CANDIDATE, MEETING ALL PRIMARY EFFICACY ENDPOINTS

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine ( mRNA-1273 ) Against Novel Coronavirus

Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures | Moderna

Immunogenicity of a DNA vaccine candidate for COVID-19

DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science (80-)

Announces Positive Interim Phase 1 Data For INO-4800 Vaccine for COVID-19

Positive-Interim-Phase-1-Data-For-INO-4800-Vaccine-for-COVID-19/default.aspx 89. Inovo Pharmaceuticals. INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate

Announces-Initiation-of-Phase-2-Segment-of-its-Phase-23-Clinical-Trial-for-its-COVID-19-DNA-Vaccine-Candidate-INO-4800-Trial-Will-Be-Funded-by-the

Exploiting virus-like particles as innovative vaccines against emerging viral infections

The promise and challenge of epitope-focused vaccines. Hum Vaccines Immunother

The spike protein of SARS-CoV -A target for vaccine and therapeutic development

Virus-like particle vaccines: immunology and formulation for clinical translation

Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate

Our Unique Technology

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

A small jab -a big effect: nonspecific immunomodulation by vaccines

Adverse Effects of Vaccines: Evidence and Causality

Risk of nontargeted infectious disease hospitalizations among US children following inactivated and live vaccines

The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: A retrospective cohort study. Hum Vaccines Immunother

This article is protected by copyright. All rights reserved

Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections

Measles-mumps-rubella vaccination and respiratory syncytial virus-associated hospital contact

Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: Population based cohort study in the Netherlands

Homologous protein domains in SARS-CoV-2 and measles, mumps and rubella viruses: preliminary evidence that MMR vaccine might provide protection against COVID-19. medRxiv

MMR Vaccine Appears to Confer Strong Protection from COVID-19 : Few Deaths from SARS-CoV-2 in Highly Vaccinated Populations MMR Vaccine Appears to Confer Strong Protection from COVID-19 : Few Deaths from SARS-CoV-2 in Highly Vaccinated Populations

Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by COVID-19 in OECD Countries? ClinicalTrials

Development of the Mycobacterium bovis BCG vaccine: Review of the historical and biochemical evidence for a genealogioal tree

To BCG or not to BCG, that is the question!". The challenge of BCG vaccination: Why can't we get it right? Paediatr Child Health (Oxford)

The BCG world atlas: A database of global BCG vaccination policies and practices

Early BCG-Denmark and Neonatal Mortality among Infants Weighing ≤2500g: A Randomized Controlled Trial

Vaccination scars associated with better survival for adults. An observational study from Guinea-Bissau

Vaccinations against smallpox and tuberculosis are associated with better long-term survival: A Danish case-cohort study 1971-2010

Nonspecific (heterologous) protection of neonatal BCG vaccination against hospitalization due to respiratory infection and sepsis

Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: A beneficial effect of BCG vaccination for girls: Community based case-control study

BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)

Impact of routine infant BCG vaccination in young generation on prevention of local COVID-19 spread in Japan: BCG vaccination prevent COVID-19 spread

TB infection and BCG vaccination: are we protected from COVID-19? Public Health

Is BCG vaccination affecting the spread and severity of COVID-19?

History of polio vaccination

Role of injectable and oral polio vaccines in polio eradication

The Effect of Oral Polio Vaccine at Birth on Infant Mortality: A Randomized Trial

Campaigns with oral polio vaccine may lower mortality and create unexpected results

National Immunization Campaigns with Oral Polio Vaccine Reduce All-Cause Mortality: A Natural Experiment within Seven Randomized Trials

Nonspecific Effects of Oral Polio Vaccine on Diarrheal Burden and Etiology Among Bangladeshi Infants

Viral interference induced by live attenuated virus vaccine (OPV) can prevent otitis media

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Coronavirus Spike Protein and Tropism Changes

Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection

GPEI -Global Polio Eradication Initiative

Measles: 142 000 people died in 2018, mostly aged under 5

Action needed now to prevent further increases in measles and measles deaths in the coming years

Delays in polio vaccination programs due to COVID-19 in Pakistan: a major threat to Pakistan's long war against polio virus

Considerations for Viral Disease Eradication: Lessons Learned and Future Strategies

COVID-19: the deadly threat of misinformation

COVID-19) Products

Update: FDA's Ongoing Commitment to Transparency for COVID-19 EUAs

COVID-19 vaccines: the importance of transparency and fact-based education

mRNA vaccines-a new era in vaccinology

COVID-19 and mRNA vaccines -First large test for a new approach

WHO R&D Blueprint: Novel Coronavirus -An International Randomised Trial of Candidate Vaccines against COVID-19.; 2020. Accessed

This article is protected by copyright. All rights reserved. certain defined study groups or endpoints that are inapplicable for their vaccine. Improving this infrastructure will help to facilitate accelerated vaccine development during a pandemic, ensure some level of comparability between different candidates, and help regulatory bodies make informed decisions.

In this review, we summarized the current vaccine landscape for COVID-19 and provided an updated snapshot of this rapidly developing field. Understanding the mechanisms by which these vaccines function help us to not only better grasp the significance of these clinical findings, but also appreciate the complexity of the efforts. As our global community will doubtlessly go on to face similar viral challenges in the future, we also identified a number of issues that need to be addressed so that we may be better prepared to respond to the next global viral challenge. The degree by which the scientific community has mobilized to study and develop effective treatments for COVID-19 has been remarkable. While it is our role as scientists to confront current challenges, we must also strive to protect our communities from future risks.

The authors would like to thank Drs. Ron Liem and Yinghui Mao (Columbia University, department of Pathobiology and Cell Biology) as well as Dr. Marcella O'Reilly (Columbia University, Cardiometabolic Genomics Center) for providing valuable feedback on an earlier version of this manuscript. We also thank Dr. Serge Cremers (Columbia University, department of Pathology) and Dr. Muredach Reilly (Columbia University, Cardiometabolic Genomics Center) for their encouragement and advice.All diagrams in this work were created using BioRender.com.

The authors declare no conflict of interest.

Wherever applicable, the nomenclature in this work follows the guidelines set by IUPHAR/BPS [142] . Key protein targets and ligands in this article are hyperlinked to This article is protected by copyright. All rights reserved.corresponding entries in http://www.guidetopharmacology.org, and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20 [142] .